insights_auto
Why is AGIO down 2,52%?
Dive Deeperchevron_right
AGIO:NASDAQ
Agios Pharmaceuticals Inc
28,04 $
arrow_downward
-2,52%(-0,73) 1D
20 қар., 13:33:49 GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for AGIO...
Open
28,01 $
High
29,14 $
Low
27,87 $
Mkt. cap
1,68 млрд
Avg. vol.
1,13 млн
Volume
248,96 м.
52-wk high
44,07 $
52-wk low
23,02 $
EPS
-6,32 $
Beta
0,66
Shares outstanding
59,81 млн
No. of employees
540
Open
28,01 $
High
29,14 $
Low
27,87 $
Mkt. cap
1,68 млрд
Avg. vol.
1,13 млн
Volume
248,96 м.
52-wk high
44,07 $
52-wk low
23,02 $
EPS
-6,32 $
Beta
0,66
Shares outstanding
59,81 млн
No. of employees
540
News stories
From web sources and news partners
Adam Feldman | Substack
·
1 күн бұрын
Inside the Federal Litigation of Five S&P 500 Giants
WSJ
·
8 сағат бұрын
S&P 500 Flirts With Correction
Los Angeles Times
·
1 сағат бұрын
S&P 500 falls 10% from record, entering correction as AI trade unravels
Investor's Business Daily
·
1 сағат бұрын
This VIX Signal Is Bullish For The S&P 500.
Profile
Agios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias. The company was founded in 2008 by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. The company tendered an initial public offering in July 2013. Wikipedia
About Agios Pharmaceuticals Inc